Glycoprotein IIB/IIIA antagonists

A bicyclic compound having a nucleus formed from two fused six membered rings, A and B, represented by the formula (II), or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof:

• wherein:
• the bicyclic nucleus of rings A and B is formula (g):
• R3 is an acid radical selected from the group consisting of:
• n is a number from 3 to 6;
• R0 is the same or different and is independently selected from hydrogen alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, amino, substituted amino, carbamyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, and ═S;
• m is 3;
• R10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, and sulfo;
• linking group —(L)— is selected from a group of from 1 to 4 chain atoms having the general formulae:
• where Z1, Z2, Z3, and Z4 are atoms independently selected from the group consisting of carbon, nitrogen, and oxygen, wherein carbon and nitrogen may be substituted with one or more non-interfering substituents;
• and
• D is a six membered ring wherein atoms D1, D2, D3, D4, D5 and D6 are independently selected from carbon, nitrogen, oxygen, or sulfur, with the proviso that at least two of D1, D2, D3, D4, D5 and D6 are carbon;
• Q1 is a basic radical selected from the group consisting of amino, imino, amidino, aminomethyleneamino, iminomethylamino, guanidino, aminoguanidino, alkylamino, dialkylamino, trialkylamino, alkylideneamino, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, beta-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl piperidyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, and any of the preceding groups substituted with amino, imino, amidino, aminomethyleneamino, iminomethylamino, guanidino, alkylamino, dialkylamino, trialkylamino, or alkylideneamino groups;
• w is an integer from 1 to 3;
• R20 are the same or different and are independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, amino, substituted amino, carbamyl, carboxy, acyl, cyano, halo, nitro, and sulfo;
• and
• is an integer from 0 to 8.

A bicyclic compound having a nucleus formed from two fused six membered rings, A and B, represented by the formula (I), or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof:

• wherein;
• the bicyclic nucleus of rings A and B is formula (g):
• R3 is an acid radical selected from the group consisting of:
• n is a number from 3 to 6;
• R0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, and ═O;
• m is 3;
• R10 is the same or different and is independently selected from hydrogen, alkyl, and halosubstituted alkyl;
• linking group —(L)— is selected from a group of from 2 to 4 chain atoms having the general formulae:
• where Z1, Z2, Z3, and Z4 are atoms independently selected from the group consisting of carbon,
• however, any questions remain, Examiner is cordially invited to contact the undersigned so that any such matters may be promptly resolved.